 |
Alternate Language Options:
|
 |
|
 |
凍結乾燥會議 - Day 3
概要 |
Day 1 |
Day 2 |
Day 3
議程 (PDF : English)
DAY THREE
Friday, January 11, 2008
7:30 am -
4:00 pm Registration Open
7:30 am - 8:15 am Breakfast Workshop or Morning Coffee
8:15 Chairpersonfs Remarks
| 8:20
Moisture Content in Freeze-Dried Product |
 |
Yves Mayeresse, Ph.D., Senior Manager, Head of Freeze-Drying, GlaxoSmithKline Biologicals (Belgium) |
|
Moisture content
is one of the major output
parameters for freeze-dried product.
The presentation first reviews
sorption and desorption isotherm. An
evaluation and validation of
moisture limit for a freeze-dried
product is then proposed. The
different available tools to analyze
moisture content inside freeze-died
product are described. An evaluation
of different lyoprotectors is done.
Their evolution during shelf life
using non destructive methods is
performed. The relevant factors
influencing final moisture content
during secondary drying of the
freeze-drying cycle are evaluated.
Finally a simple theoretical model
to explain the different results
obtained will be described.
Attendees will learn:
- A Better understanding of key
parameters influencing the
freeze-drying process
- A realistic expectation in
terms of moisture content in
regard of the formulation
- The different tools allowing
to follow moisture content for
freeze-dried product
|
| 8:50
Points to Consider on Freeze Drying
Process Design for Scale-Up |
 |
Charlie Tang, Ph.D., Sr. Research Scientist, Formulation
Development, Centocor, Inc. (J&J) |
| Manometric Temperature Measurement (MTM) yields data of product temperature and dry cake resistance in primary drying. MTM measurements can be applied to select the optimum shelf temperature, to deter-mine drying end points and to evaluate residual moisture content in secondary drying in real-time. The freeze dryer overload conditions can be estimated by calculation of heat/mass flow at the target product temperature. Therefore, MTM can serve as a powerful Process Analytical Technology for freeze-drying at laboratory and manufacturing scales. |
|
|
| 9:20
Scale-Up Considerations and Cycle
Development |
 |
Stephen
Chang, Ph.D., Senior Scientist,
MedImmune, Inc. |
|
|
|
9:50 Coffee Break in the Exhibit Hall
10:45 Poster Awards in Exhibit Hall
|
Special
In-Depth Presentation
|
| 11:00
Root Cause Analysis and Risk Assessment for
Lyophilized Product |
 |
Edward H. Trappler, President and Founder, Lyophilization
Technology, Inc. |
|
The risk of
failure and sensitivity to events
such as abhorrent conditions,
process excursions and differences
in dried product attributes
sometimes occur in routine
manufacturing is high for
lyophilized products. Such events
warrant an analysis of the root
cause and evaluation of any impact
on the final product attributes and
suitability in releasing a batch.
Knowledge of the process and product
through appropriate development
activities and the ability to assess
the impact of such events are
critical in evaluating their impact
on final product quality.
|
|
| 12:00
A Gentle PAT Approach to In-Line Control of the Lyophilization Process |
 |
Miquel Galan, R&D and Innovation Director, IMA-Telstar, S.L. |
|
A lyophilization
process is usually only specified in
terms of a erecipef (shelf
temperature and chamber pressure vs.
time). This, however, may not
guarantee repeatable conditions for
the freezing and sublimation steps.
According to the recent PAT
guidelines, there is the need to
study in depth the process in order
to develop on-line tools to enable
better monitoring and control. It is
necessary to move from intensive
property (independent of mass)
measurements (such as temperature,
pressure -partial or total-) to
parameters which are scalable and in
so doing implement the necessary
tools to control the parameters and
hence the cycle; thus permitting
real-time feedback control actions.
Two variables are key to monitoring
the lyophilization process:
sublimation interface temperature
(during the whole of primary drying
this has to be maintained below the
collapse temperature) and
sublimation mass flow (which has to
be maximized to achieve the most
cost effective cycle). With
classical monitoring tools these key
goals are not achievable. This is an
important issue because:
- Traditional lyophilization
process needs a serious
qualitative step to adapt to
this emerging PAT guidelines
initiative and in depth analysis
helps to gain process knowledge
- From simpler steady state
models up to more complex
transient ones, they open a
window into the process
assisting to assess important
lyophilization parameters
- Process can be optimized from
the initial R&D
- R&D stage of process
development tremendously
simplified (time saving)
- Industrial processes can be
monitored
- In-line closed loop control
possible
Key learning objectives:
- Hear about new and developing
technologies for Process Control
- Understand how to control
product consistency from lab
scale to full scale production
- Discover areas for potential
process and operational
optimization
|
|
12:30
Lunch on Own or Luncheon and Strategic Solutions
Presentations
|
Joint
Plenary Keynote Session
LYOPHILIZATION PROTEIN PRODUCTION
PROCESS MANAGEMENT |
| 1:45
Chairpersonfs Remarks
1:50 Policy, Regulatory and
Engineering Considerations when
Transitioning from Lab to Manufacturing
Scale
| 2:20
Vaccines vs. Biologics: Protein
Production, Process Management and
Lyophilization Considerations |
 |
Susan
Behrens, Senior Director,
Biological Sciences &
Strategy, Merck & Co., Inc. |
|
Vaccine
production shares many process
features with biologics
manufacturing. Common unit
operations include fermentation,
cell culture, chromatography,
filtration, formulation, vial
& syringe filling and
lyophilization. As the demand for
vaccine products is projected to
increase by 2X over the next 5
years, the ability to transfer
knowledge gained from large scale
protein production provides an
opportunity to maximize efficiency
of production for both product
areas.
- Synergies between biologics
and vaccine manufacture
- Vaccines vs. biologics:
Distinctive qualities and
impact on production, process
management and lyophilization
- Key supply chain issues for
both vaccines and biologic
products and how the
two interact
- Leveraging lessons from
biologics production as the
vaccine business grows
globally
|
3:00
Refreshment Break |
|
Joint
Interactive Workshop
DEVELOPING A STREAMLINED MATRIX APPROACH
FOR QUALIFICATION AND VALIDATION |
| 3:20
Interactive Case Studies for
Matrix Validation Approaches and
Challenges for Lyophilized
Products |
 |
Robert
Darius, Director, Global Quality
Assurance, GlaxoSmithKline
Biologicals |
|
The goal of the
program is to address the
challenge of whether more data be
provided while using less active
pharmaceutical product.Whether
your product is lyophilized or
not, budgetary, timing, validation
and regulatory concerns all
coalesce during the rapid
development and fast track
approval processes for
pharmaceutical development,
scale-up and new CMO approval for
pharmaceutical products. These
challenges have become
increasingly complex in the highly
competitive global
environment.Through these
interactive case scenarios,
participants will work in small
teams to review scenarios and
challenges associated with
development, implementation and
regulatory approval of matrix
validation approaches for
lyophilized products. Several
different case studies will be
provided and group input will
allow for in-depth discussion of
key points to consider.
- Reinforcement of basic
matrix validation approaches
- Exposure and use of
currently available (and
accepted) technologies to
assess key physical
formulation characteristics
- Increased understanding of
regulatory concerns and
requirements
- Use of different approaches
to assess multi-variate
challenges in validation
|
| 4:00
Interactive Team Project -
Sharing Ideas to Develop a MATRIX |
| Meeting
delegates will be given a problem
scenario and a set of questions
and discussion points. Delegates
at each table will review
scenarios and challenges
associated with development,
implementation and regulatory
approval of matrix validation
approaches. Table moderators will
interrogate the issues and
facilitate the discussion focused
on the groupfs MATRIX design. |
| Moderators: |
 |
Edward
H. Trappler, President and
Founder, Lyophilization
Technology, Inc. |
 |
Jeff
Schwegman, Ph.D., Founder/Chief
Scientific Officer, BioConvergence
LLC |
 |
Palani
Palaniappan, Ph.D., Senior
Director, Pharmaceutical Sciences,
Millennium Pharmaceuticals |
 |
Robert
Darius, Director, Global Quality
Assurance, GlaxoSmithKline
Biologicals |
|
Narlin
Beaty, Ph.D., Managing Partner,
Mechanical Engineering,
Qualification Process Solutions,
LLC |
|
5:00 Closing Comments and Take Home
Message
|
 |
|